Introduction
Current management of hypertension in patients with renal impairment is often unsatisfactory and associated with unacceptable adverse effects from drugs. Endralazine is a new peripheral vasodilator chemically related to hydralazine but not dependent upon acetylation for its metabolism (Salzmann, 1973; Baldeck and Kalberer, 1978) . The present study describes our experience with endralazine after one month in 21 patients with uncontrolled hypertension and chronic renal failure.
Patients and methods
Twenty-one patients who were attending the Renal Clinic at Southmead Hospital were studied. Their underlying renal disease is listed in the 
Discussion
Hypertension is a common problem in patients with renal impairment, which if inadequately controlled can lead to a more rapid decline in the patient's renal function (Moyer et al., 1956 ). Treatment in these patients can be difficult because of the severity of the hypertension and the side effects of current drug regimes. The vasodilator hydralazine is in common use in the treatment of hypertension resistant to diuretics and beta-blockers. However, hydralazine often causes unpleasant haemodynamic symptoms such as headache and postural hypotension. Treatment with hydralazine is associated with seroconversion of antinuclear factor and, more rarely, development of a lupus-like syndrome (Perry, 1973) . This effect is related to exposure to free drug and the major excretion of hydralazine is as the acetylated metabolite. Patients who acetylate the drug slowly are therefore those most at risk of developing this adverse effect (Perry et al., 1970; Bing et al., 1980) . The present study has examined a new vasodilator, endralazine which is chemically related to hydralazine but for which acetylation is not a major route of metabolism (Baldeck and Kalberer, 1978) .
Twenty-one patients entered the study and one was withdrawn after 2 weeks for failing to comply with regular drug taking. At the end of one month all but one patient had a reduction in lying and standing systolic and diastolic blood pressure while taking endralazine 7-5 mg to 60 mg daily in conjunction with beta-adrenergic blocker. Before the study nine patients were taking hydralazine, three minoxidil, one diazoxide and three methyldopa. None of these patients has had to return to their previous drugs while receiving endralazine Though endralazine is a potent vasodilator, oedema and weight gain were not seen in this study. Severe symptomatic side effects did not develop during the 4 weeks of the study and have not been apparent in those patients who have continued therapy for up to 6 months. Fourteen patients in the study who had had troublesome side effects with their previous regime felt so well while taking endralazine that they have asked to be continued on the drug. We conclude that endralazine is a potent antihypertensive drug when used in conjunction with beta-adrenergic blockage. Further long-term studies are in progress.
